Dr. Ka Ho Gary Ho

Analytical Development Scientist
Piramal Pharma Solutions, Grangemouth, Scotland

Highest Degree
Ph.D. in Pharmacology from Strathclyde University, UK

My URL
https://livedna.org/44.23749

Share this Profile

Area of Interest:

Pharmacology and Toxicology
Molecular Pharamcology
Toxicology
Biomedical Sciences
Biomarkers

Selected Publications

  1. Ng, P.Y., K. McIntosh, K.H. Ho, A. Paul and R. Plevin, 2017. Purinergic P2Y11 mediated inhibition of interleukin-1β stimulated c-Jun N-terminal kinase activity in primary cultures of human endothelial cells. Eur. J. Pharmacol., (In Press). .

  2. McIntosh, K., R. Scott, K.H. Ho, A. Paul and R. Plevin, 2017. The therapeutic potential of regulating Inhibitory kappa B kinase alpha (IKKα) in prostate cancer. Patent Applic. (In Press). .

  3. Anthony, N.G., J. Baiget, G. Berretta, M. Boyd and D. Breen et al., 2017. Inhibitory Kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers. J. Med. Chem., 60: 7043-7066.
    CrossRef  |  Direct Link  |  

  4. Gamble, C., K. McIntosh, R. Scott, K.H. Ho, R. Plevin and A. Paul, 2012. Inhibitory kappa B Kinases as targets for pharmacological regulation. Br. J. Pharmacol., 165: 802-819.
    CrossRef  |  Direct Link  |  
Member since April, 2018